Stoke Therapeutics STOK 深 滬
等待開盤 10-07 09:30:00 美东时间
26.81
+1.250
+4.89%
華盛通- 最 高28.00
- 今 開26.85
- 成交量 102.36万股
- 最 低 26.29
- 昨 收 25.56
- 總市值 14.64亿
- 52周最高 28.00
- 市盈率 靜 --
- 換手率 1.87%
- 52周最低 5.35
- 委 比 -44.90%
- 總股本 5459.69万
- 歷史最高 71.58
- 量 比 1.05
- 振 幅 6.69%
- 歷史最低 3.35
- 每 手 1
- 風險率 4.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stoke Therapeutics Names Ian F. Smith CEO
Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial ExecutionArthur Tzianabos Resumes Chairman of the Board RoleBEDFORD, Mass.--(BUSINESS WIRE)--
10-06 19:36
Reported Earlier: Biogen And Stoke Therapeutics Report Durable Seizure Reductions And Cognitive Improvements With Zorevunersen In Dravet Syndrome; Zorevunersen Generally Well Tolerated Across All Studies; Data Support Pivotal Phase 3 EMPORER Study Now Underway
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –– Substantial increase in
09-02 21:56
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
Zorevunersen, an investigational antisense oligonucleotide, shows potential as a disease-modifying therapy for Dravet syndrome, according to 3-year data from open-label extension studies. The studies demonstrate durable seizure reductions, improvements in cognition and behavior, and increased seizure-free days. Biogen Inc. and Stoke Therapeutics, Inc. announced the presentation of new clinical data at the 36th International Epilepsy Congress (IEC...
08-25 11:00
美股牛股 | Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray涨超30%
加密货币交易所Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray隔夜涨超30%，周内涨超90%，特朗普拟将大麻改为低危药物>>
08-14 15:08
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Where Stoke Therapeutics Stands With Analysts
Throughout the last three months, 4 analysts have evaluated Stoke Therapeutics ...
08-14 04:01
Stoke Therapeutics Q2 EPS $(0.40) Beats $(0.46) Estimate, Sales $13.817M Beat $9.967M Estimate
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.46) by 13.61 percent. This is a 13.04 percent increase over losses of $(0.46) per share
08-13 04:02
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
A Look Ahead: Stoke Therapeutics's Earnings Forecast
Stoke Therapeutics (NASDAQ:STOK) is preparing to release its quarterly earnings...
08-12 00:03
Stoke Therapeutics And Biogen Announced That The First Patient Has Been Dosed In The Global Phase 3 EMPEROR Study Of Zorevunersen For Dravet Syndrome
Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.Dravet syndrome is a rare genetic disease characterized by refractory seizures and
08-11 19:05
